{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T22:06:30Z","timestamp":1771970790471,"version":"3.50.1"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11602-7","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:47:45Z","timestamp":1771922865000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of macrophages and dendritic cells in autoimmune diseases: a specific focus on tumor necrosis factor targeting therapies against rheumatoid arthritis"],"prefix":"10.1007","volume":"53","author":[{"given":"Elif Naz","family":"Y\u00fccel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Furkan","family":"Ayaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"11602_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","volume":"6","author":"Q Guo","year":"2018","unstructured":"Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J (2018) Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 6:15. https:\/\/pubmed.ncbi.nlm.nih.gov\/29736302\/","journal-title":"Bone Res"},{"issue":"1","key":"11602_CR2","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/S0720-048X(98)00040-0","volume":"27","author":"PN Scutellari","year":"1998","unstructured":"Scutellari PN, Orzincolo C (1998) Rheumatoid arthritis: sequences. Eur J Radiol 27(1):S31\u2013S38. https:\/\/pubmed.ncbi.nlm.nih.gov\/9652499\/","journal-title":"Eur J Radiol"},{"key":"11602_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/path.2287","volume":"214","author":"JR Bradley","year":"2008","unstructured":"Bradley JR (2008) TNF-mediated inflammatory disease. J Pathol 214:149\u2013160. https:\/\/pubmed.ncbi.nlm.nih.gov\/18161752\/","journal-title":"J Pathol"},{"key":"11602_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/intimm\/dxu102","volume":"27","author":"C Monaco","year":"2015","unstructured":"Monaco C, Nanchahal J, Taylor P, Feldmann M, Anti (2015) -TNF therapy: past, present and future. Int Immunol 27:55\u201362. https:\/\/pubmed.ncbi.nlm.nih.gov\/25381461\/","journal-title":"Int Immunol"},{"key":"11602_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","volume":"14","author":"M Feldmann","year":"1996","unstructured":"Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397\u2013440. https:\/\/pubmed.ncbi.nlm.nih.gov\/8717510\/","journal-title":"Annu Rev Immunol"},{"key":"11602_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fmed.2019.00014","volume":"6","author":"R Celis","year":"2019","unstructured":"Celis R, Cuervo A, Ram\u00edrez J, Ca\u00f1ete JD (2019) Psoriatic synovitis: singularity and potential clinical implications. Front Med 6:14. https:\/\/pubmed.ncbi.nlm.nih.gov\/30873462\/","journal-title":"Front Med"},{"key":"11602_CR7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJM200103223441207https","volume":"344","author":"EHS Choy","year":"2001","unstructured":"Choy EHS, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907\u2013916. https:\/\/doi.org\/10.1056\/NEJM200103223441207https","journal-title":"N Engl J Med"},{"key":"11602_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3389\/fendo.2019.00252","volume":"10","author":"M Porchas-Quijada","year":"2019","unstructured":"Porchas-Quijada M et al (2019) IgG anti-ghrelin immune complexes are increased in rheumatoid arthritis patients under biologic therapy and are related to clinical and metabolic markers. Front Endocrinol (Lausanne) 10:252. https:\/\/pubmed.ncbi.nlm.nih.gov\/31057488\/","journal-title":"Front Endocrinol (Lausanne)"},{"key":"11602_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cca.2016.02.010","volume":"455","author":"S Mateen","year":"2016","unstructured":"Mateen S et al (2016) Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clin Chim Acta 455:161\u2013171. https:\/\/pubmed.ncbi.nlm.nih.gov\/26883280\/","journal-title":"Clin Chim Acta"},{"key":"11602_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41584-020-0413-5","volume":"16","author":"G Nygaard","year":"2020","unstructured":"Nygaard G, Firestein GS (2020) Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat Rev Rheumatol 16:316\u2013333. https:\/\/pubmed.ncbi.nlm.nih.gov\/32393826\/","journal-title":"Nat Rev Rheumatol"},{"key":"11602_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4081\/reumatismo.2018.1106","volume":"70","author":"E Marcucci","year":"2018","unstructured":"Marcucci E et al (2018) Extra-articular rheumatoid arthritis. Reumatismo 70:212\u2013224. https:\/\/pubmed.ncbi.nlm.nih.gov\/30570239\/","journal-title":"Reumatismo"},{"key":"11602_CR12","doi-asserted-by":"publisher","first-page":"655477","DOI":"10.3389\/fimmu.2021.655477","volume":"12","author":"J Tu","year":"2021","unstructured":"Tu J, Huang W, Zhang W, Mei J, Zhu C (2021) A tale of two immune cells in rheumatoid arthritis: the crosstalk between macrophages and T cells in the synovium. Front Immunol 12:655477. https:\/\/pubmed.ncbi.nlm.nih.gov\/34054882\/","journal-title":"Front Immunol"},{"key":"11602_CR13","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388:2023\u20132038 PMID: 26850741. https:\/\/pubmed.ncbi.nlm.nih.gov\/26850741\/","journal-title":"Lancet"},{"key":"11602_CR14","doi-asserted-by":"publisher","first-page":"100098","DOI":"10.1016\/j.jtauto.2020.100098","volume":"3","author":"MI Edilova","year":"2020","unstructured":"Edilova MI, Akram A, Abdul-Sater AA (2020) Macrophages and dendritic cells in autoimmune diseases: A molecular perspective. J Transl Autoimmun 3:100098. https:\/\/doi.org\/10.1016\/j.jtauto.2020.100098","journal-title":"J Transl Autoimmun"},{"key":"11602_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-023-01331-9","volume":"8","author":"Q Ding","year":"2023","unstructured":"Ding Q, Hu W, Wang R, Yang Q, Zhu M, Li M et al (2023) Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduct Target Ther 8:68. https:\/\/doi.org\/10.1038\/s41392-023-01331-9","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"11602_CR16","first-page":"529","volume":"376","author":"GS Firestein","year":"2017","unstructured":"Firestein GS, McInnes IB (2017) Immunopathogenesis of rheumatoid arthritis. N Engl J Med 376(6):529\u2013540. https:\/\/pubmed.ncbi.nlm.nih.gov\/28228278\/","journal-title":"N Engl J Med"},{"key":"11602_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00281-022-00912-0","volume":"44","author":"L Padyukov","year":"2022","unstructured":"Padyukov L (2022) Genetics of rheumatoid arthritis. Semin Immunopathol 44:47\u201362. https:\/\/doi.org\/10.1007\/s00281-022-00912-0","journal-title":"Semin Immunopathol"},{"issue":"10","key":"11602_CR18","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1093\/rheumatology\/keaa232","volume":"59","author":"LE Dedmon","year":"2020","unstructured":"Dedmon LE (2020) The genetics of rheumatoid arthritis. Rheumatology (Oxford) 59(10):2661\u20132670","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"11602_CR19","first-page":"1","volume":"45","author":"CG Parks","year":"2019","unstructured":"Parks CG, Deane KD (2019) Environmental and lifestyle risk factors for rheumatoid arthritis. Rheumatic Disease Clin North Am 45(1):1\u201315 PMID: 27886827","journal-title":"Rheumatic Disease Clin North Am"},{"issue":"7488","key":"11602_CR20","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nrrheum.2014.21","volume":"506","author":"Y Okada","year":"2014","unstructured":"Okada Y, Wu D, Trynka G et al (2014) Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506(7488):376\u2013381. https:\/\/doi.org\/10.1038\/nrrheum.2014.21","journal-title":"Nature"},{"key":"11602_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/ar86","volume":"2","author":"RW Kinne","year":"2000","unstructured":"Kinne RW, Br\u00e4uer R, Stuhlm\u00fcller B, Palombo-Kinne E, Burmester GR (2000) Macrophages in rheumatoid arthritis. Arthritis Res 2:189\u2013202. https:\/\/doi.org\/10.1186\/ar86","journal-title":"Arthritis Res"},{"issue":"7446","key":"11602_CR22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature12034","volume":"496","author":"TA Wynn","year":"2013","unstructured":"Wynn TA, Chawla A, Pollard JW (2013) Macrophage biology in development, homeostasis and disease. Nature 496(7446):445\u2013455. https:\/\/doi.org\/10.1038\/nature12034","journal-title":"Nature"},{"issue":"6","key":"11602_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.33696\/immunology.5.184","volume":"5","author":"M Jalalvand","year":"2023","unstructured":"Jalalvand M, Khanmohammadi S, Akhtari M, Farhadi E, Jamshidi A, Mahmoudi M (2023) Macrophages in bone and synovial inflammation in rheumatoid arthritis. J Cell Immunol 5(6):184\u2013192. https:\/\/doi.org\/10.33696\/immunology.5.184","journal-title":"J Cell Immunol"},{"key":"11602_CR24","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/rheumatology\/kes304","volume":"52","author":"JL Davignon","year":"2013","unstructured":"Davignon JL, Hayder M, Baron M, Boyer JF, Constantin A, Apparailly F, Poupot R, Cantagrel A (2013) Targeting monocytes\/macrophages in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 52:590\u2013598. https:\/\/doi.org\/10.1093\/rheumatology\/kes304","journal-title":"Rheumatology (Oxford)"},{"key":"11602_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/art.1780390116","volume":"39","author":"D Mulherin","year":"1996","unstructured":"Mulherin D, Fitzgerald O, Bresnihan B (1996) Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 39:115\u2013124. https:\/\/pubmed.ncbi.nlm.nih.gov\/8546720\/","journal-title":"Arthritis Rheum"},{"key":"11602_CR26","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1002\/1529-0131(200012)43:12<2619::AID-ANR1>3.0.CO;2-V","volume":"43","author":"PP Tak","year":"2000","unstructured":"Tak PP, Bresnihan B (2000) The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 43:2619\u20132633. https:\/\/pubmed.ncbi.nlm.nih.gov\/11145019\/","journal-title":"Arthritis Rheum"},{"key":"11602_CR27","first-page":"00052","volume":"2011","author":"A Kennedy","year":"2011","unstructured":"Kennedy A, Fearon U, Veale DJ, Godson C (2011) Macrophages in synovial inflammation. Front Immunol 2011:00052. https:\/\/pubmed.ncbi.nlm.nih.gov\/22566842\/","journal-title":"Front Immunol"},{"key":"11602_CR28","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/mt.2010.27","volume":"18","author":"SS Kim","year":"2010","unstructured":"Kim SS, Ye C, Kumar P, Chiu I, Subramanya S, Wu H, Shankar P, Manjunath N (2010) Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther 18:993\u20131001. https:\/\/pubmed.ncbi.nlm.nih.gov\/20216529\/","journal-title":"Mol Ther"},{"key":"11602_CR29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/wnan.157","volume":"3","author":"CT Pham","year":"2011","unstructured":"Pham CT (2011) Nanotherapeutic approaches for the treatment of rheumatoid arthritis. Wiley Interdiscip Rev Nanomed Nanobiotechnol 3:607\u2013619. https:\/\/doi.org\/10.1002\/wnan.157. https:\/\/pubmed.ncbi.nlm.nih.gov\/21837725\/","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"7","key":"11602_CR30","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00018-019-03235-w","volume":"77","author":"K Van Raemdonck","year":"2020","unstructured":"Van Raemdonck K, Umar S, Palasiewicz K, Volkov S, Volin MV, Arami S et al (2020) CCL21\/CCR7 Signaling in Macrophages Promotes Joint Inflammation and Th17-Mediated Osteoclast Formation in Rheumatoid Arthritis. Cell Mol Life Sci 77(7):1387\u20131399. https:\/\/doi.org\/10.1007\/s00018-019-03235-w","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"11602_CR31","doi-asserted-by":"publisher","first-page":"e12854","DOI":"10.1111\/cpr.12854","volume":"53","author":"X Yang","year":"2020","unstructured":"Yang X, Chang Y, Wei W (2020) Emerging role of targeting macrophages in rheumatoid arthritis: Focus on polarization, metabolism and apoptosis. Cell Prolif 53(7):e12854. https:\/\/doi.org\/10.1111\/cpr.12854","journal-title":"Cell Prolif"},{"issue":"9","key":"11602_CR32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41584-020-0421-0","volume":"16","author":"S Culemann","year":"2020","unstructured":"Culemann S, Gr\u00fcneboom A, Kr\u00f6nke G (2020) Origin and function of synovial macrophages in rheumatoid arthritis. Nat Rev Rheumatol 16(9):509\u2013519. https:\/\/doi.org\/10.1038\/s41584-020-0421-0","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"11602_CR33","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1002\/art.38762","volume":"66","author":"JR Glossop","year":"2014","unstructured":"Glossop JR, Emes RD, Nixon NB, Packham JC, Adams SE, Farrell WE (2014) Genome-wide DNA methylation profiling in rheumatoid arthritis reveals hypomethylation of type I interferon\u2013regulated genes in monocytes. Arthritis Rheum 66(10):2766\u20132774. https:\/\/doi.org\/10.1002\/art.38762. https:\/\/pubmed.ncbi.nlm.nih.gov\/24853221\/","journal-title":"Arthritis Rheum"},{"issue":"6","key":"11602_CR34","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/annrheumdis-2011-200703","volume":"71","author":"A Crilly","year":"2012","unstructured":"Crilly A, Burns E, Nickdel MB, Lockhard JC, Perry ME, Ferrell PW et al (2012) PAR (2) Expression in Peripheral Blood Monocytes of Patients With Rheumatoid Arthritis. Ann Rheum Dis 71(6):1049\u20131054. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200703","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"11602_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/03009742.2013.803149","volume":"43","author":"T Ellingsen","year":"2014","unstructured":"Ellingsen T, Hansen I, Thorsen J, M\u00f8ller BK, Tarp T, Lottenburger T et al (2014) Upregulated Baseline Plasma CCL19 and CCR7 Cell-Surface Expression on Monocytes in Early Rheumatoid Arthritis Normalized During Treatment and CCL19 Correlated With Radiographic Progression. Scand J Rheumatol 43(2):91\u2013100. https:\/\/pubmed.ncbi.nlm.nih.gov\/23980529\/","journal-title":"Scand J Rheumatol"},{"issue":"7","key":"11602_CR36","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","volume":"20","author":"a Zhang","year":"2019","unstructured":"Zhang a, Wei F, Slowikowski KK (2019) Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol 20(7):928\u2013942","journal-title":"Nat Immunol"},{"issue":"491","key":"11602_CR37","doi-asserted-by":"publisher","first-page":"eaau8587","DOI":"10.1126\/scitranslmed.aau8587","volume":"11","author":"D Kuo","year":"2019","unstructured":"Kuo D, Ding J, Cohn IS et al (2019) HBEGF+ macrophages in rheumatoid arthritis induce fibroblast invasiveness. Sci Transl Med 11(491):eaau8587. https:\/\/doi.org\/10.1126\/scitranslmed.aau8587","journal-title":"Sci Transl Med"},{"key":"11602_CR38","unstructured":"NIH Research Matters (2019) Understanding rheumatoid arthritis at the cellular level. https:\/\/www.nih.gov\/news-events\/nih-research-matters\/understanding-rheumatoid-arthritis-cellular-level"},{"issue":"10","key":"11602_CR39","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nri3529","volume":"13","author":"M Merad","year":"2013","unstructured":"Merad M, Sathe P, Helft J et al (2013) The dendritic cell lineage: Ontogeny and function of dendritic cells. Nat Rev Immunol 13(10):683\u2013696. https:\/\/doi.org\/10.1038\/nri3529","journal-title":"Nat Rev Immunol"},{"key":"11602_CR40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13075-023-03159-8","volume":"25","author":"Z Wang","year":"2023","unstructured":"Wang Z, Zhang J, An F, Zhang J, Meng X, Liu S, Xia R, Wang G, Yan C (2023) The mechanism of dendritic cell-T cell crosstalk in rheumatoid arthritis. Arthritis Res Ther 25:193. https:\/\/doi.org\/10.1186\/s13075-023-03159-8","journal-title":"Arthritis Res Ther"},{"issue":"290","key":"11602_CR41","doi-asserted-by":"publisher","first-page":"290ra87","DOI":"10.1126\/scitranslmed.aaa9301","volume":"7","author":"H Benham","year":"2015","unstructured":"Benham H, Nel HJ, Law SC et al (2015) Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype\u2013positive rheumatoid arthritis patients. Sci Transl Med 7(290):290ra87. https:\/\/doi.org\/10.1126\/scitranslmed.aaa9301","journal-title":"Sci Transl Med"},{"key":"11602_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10","volume":"20","author":"N Parameswaran","year":"2010","unstructured":"Parameswaran N, Patial S (2010) Tumor necrosis factor-\u03b1 signaling in macrophages. Crit Rev Eukaryot Gene Expr 20:87\u2013103. https:\/\/pubmed.ncbi.nlm.nih.gov\/18063842\/","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"11602_CR43","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/rheumatology\/kes304","volume":"52","author":"JL Davignon","year":"2013","unstructured":"Davignon JL, Hayder M, Baron M, Boyer JF, Constantin A, Apparailly F et al (2013) Targeting monocytes\/macrophages in the treatment of rheumatoid arthritis. Rheumatology 52:590\u2013598. https:\/\/pubmed.ncbi.nlm.nih.gov\/23204551\/","journal-title":"Rheumatology"},{"key":"11602_CR44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","volume":"19","author":"M Feldmann","year":"2001","unstructured":"Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163\u2013196. https:\/\/pubmed.ncbi.nlm.nih.gov\/11244034\/","journal-title":"Annu Rev Immunol"},{"key":"11602_CR45","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/rheumatology\/kem298","volume":"47","author":"RE Simmonds","year":"2008","unstructured":"Simmonds RE, Foxwell BM (2008) Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology 47:584\u2013590. https:\/\/pubmed.ncbi.nlm.nih.gov\/18234712\/","journal-title":"Rheumatology"},{"issue":"8657","key":"11602_CR46","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","volume":"334","author":"FM Brennan","year":"1989","unstructured":"Brennan FM, Chantry D, Jackson A, Maini RN, Feldmann M (1989) Inhibitory effect of tumor necrosis factor alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 334(8657):244\u2013247. https:\/\/pubmed.ncbi.nlm.nih.gov\/2569055\/","journal-title":"Lancet"},{"issue":"5","key":"11602_CR47","first-page":"613","volume":"38","author":"DM Butler","year":"1995","unstructured":"Butler DM, Maini RN, Feldmann M, Brennan FM (1995) Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Arthritis Rheum 38(5):613\u2013621. https:\/\/pubmed.ncbi.nlm.nih.gov\/8789287\/","journal-title":"Arthritis Rheum"},{"issue":"1","key":"11602_CR48","first-page":"113","volume":"175","author":"RO Williams","year":"1992","unstructured":"Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. J Exp Med 175(1):113\u2013120. https:\/\/pubmed.ncbi.nlm.nih.gov\/1409699\/","journal-title":"J Exp Med"},{"key":"11602_CR49","first-page":"153","volume":"175","author":"GJ Thorbecke","year":"1992","unstructured":"Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA (1992) Inhibition of collagen-induced arthritis by anti\u2013tumor necrosis factor monoclonal antibody. J Exp Med 175:153\u2013160","journal-title":"J Exp Med"},{"issue":"3","key":"11602_CR50","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1074-7613(00)80038-2","volume":"10","author":"D Kontoyiannis","year":"1999","unstructured":"Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G (1999) Impaired on\/off regulation of TNF biosynthesis in mice lacking the AU-rich elements of the TNF mRNA. Immunity 10(3):387\u2013398. https:\/\/pubmed.ncbi.nlm.nih.gov\/10204494\/","journal-title":"Immunity"},{"issue":"12","key":"11602_CR51","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/art.1780361206","volume":"36","author":"MJ Elliott","year":"1993","unstructured":"Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Breedveld FC et al (1993) Recombinant chimeric anti\u2013tumor necrosis factor alpha monoclonal antibody in rheumatoid arthritis. Arthritis Rheum 36(12):1681\u20131690. https:\/\/pubmed.ncbi.nlm.nih.gov\/8250987\/","journal-title":"Arthritis Rheum"},{"issue":"9194","key":"11602_CR52","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"RN Maini","year":"1999","unstructured":"Maini RN, St Clair EW, Breedveld FC, Furst DE, Kalden JR, Weisman MH et al (1999) Infliximab (chimeric anti\u2013tumor necrosis factor alpha monoclonal antibody) in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Lancet 354(9194):1932\u20131939","journal-title":"Lancet"},{"issue":"22","key":"11602_CR53","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343(22):1594\u20131602","journal-title":"N Engl J Med"},{"issue":"3","key":"11602_CR54","first-page":"628","volume":"54","author":"KL Hyrich","year":"2006","unstructured":"Hyrich KL, Lunt M, Watson KD, Symmons DPM (2006) British Society for Rheumatology Biologics Register.Loss of response to anti\u2013TNF therapy in patients with rheumatoid arthritis: real-world results from the first year of biologics use. Arthritis Rheum 54(3):628\u2013635","journal-title":"Arthritis Rheum"},{"key":"11602_CR55","doi-asserted-by":"publisher","first-page":"591365","DOI":"10.3389\/fimmu.2020.591365","volume":"11","author":"F Zamri","year":"2020","unstructured":"Zamri F, de Vries TJ (2020) Use of TNF Inhibitors in Rheumatoid Arthritis and Implications for the Periodontal Status: For the Benefit of Both? Front. Immunol 11:591365. https:\/\/doi.org\/10.3389\/fimmu.2020.591365. https:\/\/pubmed.ncbi.nlm.nih.gov\/33193432\/","journal-title":"Immunol"},{"key":"11602_CR56","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/path.2287","volume":"214","author":"JR Bradley","year":"2008","unstructured":"Bradley JR (2008) TNF-mediated inflammatory disease. J Pathol 214:149\u2013160. https:\/\/doi.org\/10.1002\/path.2287. https:\/\/pubmed.ncbi.nlm.nih.gov\/18161752\/","journal-title":"J Pathol"},{"key":"11602_CR57","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3892\/br.2012.42","volume":"1","author":"X Ma","year":"2013","unstructured":"Ma X, Xu S (2013) TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep 1:177\u2013184. https:\/\/doi.org\/10.3892\/br.2012.42","journal-title":"Biomed Rep"},{"key":"11602_CR58","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00296-009-1111-4.https","volume":"30","author":"A Wiens","year":"2010","unstructured":"Wiens A, Correr CJ, Venson R, Otuki MF, Pontarolo R (2010) A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis. Rheumatol Int 30:1063\u20131070. https:\/\/doi.org\/10.1007\/s00296-009-1111-4.https","journal-title":"Rheumatol Int"},{"key":"11602_CR59","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/art.20982","volume":"52","author":"JS Smolen","year":"2005","unstructured":"Smolen JS, Han C, Bala M et al (2005) ATTRACT Study Group Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52:1020\u20131030. https:\/\/doi.org\/10.1002\/art.20982","journal-title":"Arthritis Rheum"},{"key":"11602_CR60","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26\u201337. https:\/\/doi.org\/10.1002\/art.21519","journal-title":"Arthritis Rheum"},{"issue":"8","key":"11602_CR61","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrrheum.2016.91","volume":"12","author":"IA Udalova","year":"2016","unstructured":"Udalova IA, Mantovani A, Feldmann M (2016) Macrophages in rheumatoid arthritis: A multifaceted therapeutic target. Nat Rev Rheumatol 12(8):472\u2013485. https:\/\/doi.org\/10.1038\/nrrheum.2016.91","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"11602_CR62","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10","volume":"20","author":"N Parameswaran","year":"2010","unstructured":"Parameswaran N, Patial S (2010) Tumor necrosis factor-\u03b1 signaling in macrophages. Crit Rev Eukaryot Gene Expr 20(2):87\u2013103. https:\/\/doi.org\/10.1615\/critreveukargeneexpr.v20.i2.10","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"11602_CR63","first-page":"19","volume":"101","author":"WY Tseng","year":"2018","unstructured":"Tseng WY, Huang YS, Lin HH, Luo SF, McCann F, McNamee K, Clanchy F, Williams R (2018) TNFR signalling and its clinical implications. Cytokine 101, 19\u201325. https:\/\/pubmed.ncbi.nlm.nih.gov\/33730773\/","journal-title":"Cytokine 2018"},{"key":"11602_CR64","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.4049\/jimmunol.175.8.5024","volume":"175","author":"M Zakharova","year":"2005","unstructured":"Zakharova M, Ziegler HK (2005) Paradoxical anti-inflammatory actions of TNF-alpha via TNF receptor 1 in macrophages and dendritic cells. J Immunol 175:5024\u20135033. https:\/\/academic.oup.com\/jimmunol","journal-title":"J Immunol"},{"key":"11602_CR65","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.17023.1","volume":"8","author":"J Holbrook","year":"2019","unstructured":"Holbrook J, Lara-Reyna S, Jarosz-Griffiths H, McDermott M (2019) Tumour necrosis factor signalling in health and disease. F1000Res 8:F1000. https:\/\/doi.org\/10.12688\/f1000research.17023.1","journal-title":"F1000Res"},{"key":"11602_CR66","doi-asserted-by":"crossref","unstructured":"Alshevskaya A, Lopatnikova J, Zhukova J, Chumasova O, Shkaruba N, Sizikov A, Evsegneeva I, Gladkikh V, Karaulov A, Sennikov SV (2019) Co-expression profile of TNF membrane-bound receptors type 1 and 2 in rheumatoid arthritis on immunocompetent cells subsets. Int J Mol Sci 21:288","DOI":"10.3390\/ijms21010288"},{"key":"11602_CR67","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/art.40793","volume":"71","author":"MP Ashton","year":"2019","unstructured":"Ashton MP, Eugster A, Dietz S, Loebel D, Lindner A, Kuehn D, Taranko AE, Heschel B, Gavrisan A, Ziegler A-G et al (2019) Association of dendritic cell signatures with autoimmune inflammation revealed by single-cell profiling. Arthritis Rheumatol 71:817\u2013828. https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1002\/art.40793","journal-title":"Arthritis Rheumatol"},{"key":"11602_CR68","doi-asserted-by":"publisher","unstructured":"Figueiredo ML (2024) Applications of single-cell RNA sequencing in rheumatoid arthritis. Frontiers in Immunology 15:1491318. https:\/\/doi.org\/10.3389\/fimmu.2024.1491318","DOI":"10.3389\/fimmu.2024.1491318"},{"key":"11602_CR69","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.immuni.2019.08.008","volume":"51","author":"CA Dutertre","year":"2019","unstructured":"Dutertre CA, Becht E, Irac SE, Khalilnezhad A, Narang V, Khalilnezhad S, Ng PY, van den Hoogen LL, Leong JY, Lee B et al (2019) Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells. Immunity 51:573\u2013589e8. https:\/\/pubmed.ncbi.nlm.nih.gov\/31474513\/","journal-title":"Immunity"},{"key":"11602_CR70","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/s1074-7613(00)80588-9","volume":"9","author":"A F\u00fctterer","year":"1998","unstructured":"F\u00fctterer A, Mink K, Luz A, Kosco-Vilbois MH, Pfeffer K (1998) The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 9:59\u201370. https:\/\/doi.org\/10.1016\/s1074-7613(00)80588-9","journal-title":"Immunity"},{"key":"11602_CR71","doi-asserted-by":"publisher","first-page":"R211","DOI":"10.1186\/ar3188","volume":"12","author":"S Visvanathan","year":"2010","unstructured":"Visvanathan S, Rahman MU, Keystone E et al (2010) Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther 12:R211. https:\/\/doi.org\/10.1186\/ar3188","journal-title":"Arthritis Res Ther"},{"key":"11602_CR72","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1007\/s00296-011-2033-5","volume":"32","author":"S Kleinert","year":"2012","unstructured":"Kleinert S, Tony HP, Krause A et al (2012) Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study. Rheumatol Int 32:2759\u20132767. https:\/\/doi.org\/10.1007\/s00296-011-2033-5","journal-title":"Rheumatol Int"},{"key":"11602_CR73","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1136\/ard.2007.080440","volume":"67","author":"CA Wijbrandts","year":"2008","unstructured":"Wijbrandts CA, Dijkgraaf MG, Kraan MC et al (2008) The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumor necrosis factor alpha expression in the synovium. Ann RheumDis 67:1139\u20131144. https:\/\/doi.org\/10.1136\/ard.2007.080440","journal-title":"Ann RheumDis"},{"key":"11602_CR74","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10","volume":"20","author":"N Parameswaran","year":"2010","unstructured":"Parameswaran N, Patial S (2010) Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr 20:87\u2013103 Tumor necrosis factor-\u03b1 signaling in macrophages - PubMed","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"1","key":"11602_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semarthrit.2012.02.002","volume":"42","author":"R Dulai","year":"2012","unstructured":"Dulai R et al (2012) The effect of tumor necrosis factor-\u03b1 antagonists on arterial stiffness in rheumatoid arthritis: a literature review. Semin Arthritis Rheum 42(1):1\u20138","journal-title":"Semin Arthritis Rheum"},{"key":"11602_CR76","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1600-065X.2008.00626.x","volume":"223","author":"M Feldmann","year":"2008","unstructured":"Feldmann M, Maini RN (2008) TNF and rheumatoid arthritis: a foundation for therapeutic success. Immunol Rev 223:7\u201319","journal-title":"Immunol Rev"},{"key":"11602_CR77","unstructured":"Alqahtani SA, Habeeb AM, Alghamdi AA, Alanazi MA (2024) Tumor Necrosis Factor (TNF) Inhibitors. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482425\/"},{"key":"11602_CR78","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/14740338.2017.1273899","volume":"16","author":"J Braun","year":"2017","unstructured":"Braun J, Kay J (2017) The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. Expert Opin Drug Saf 16:289\u2013302","journal-title":"Expert Opin Drug Saf"},{"key":"11602_CR79","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B","volume":"44","author":"D Baeten","year":"2001","unstructured":"Baeten D et al (2001) Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 44:186\u2013195","journal-title":"Arthritis Rheum"},{"key":"11602_CR80","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35\u201345. https:\/\/pubmed.ncbi.nlm.nih.gov\/12528101\/","journal-title":"Arthritis Rheum"},{"key":"11602_CR81","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/annrheumdis-2012-201445","volume":"72","author":"PA van Schouwenburg","year":"2013","unstructured":"van Schouwenburg PA et al (2013) Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 72:104\u2013109. https:\/\/pubmed.ncbi.nlm.nih.gov\/22759910\/","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"11602_CR82","doi-asserted-by":"publisher","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","volume":"130","author":"LW Moreland","year":"1999","unstructured":"Moreland LW et al (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130(6):478\u2013486","journal-title":"Ann Intern Med"},{"issue":"2","key":"11602_CR83","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/00002512-200623020-00006","volume":"23","author":"MH Schiff","year":"2006","unstructured":"Schiff MH et al (2006) Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging 23(2):167\u2013178","journal-title":"Drugs Aging"},{"key":"11602_CR84","unstructured":"Genovese MC et al (2005) Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol. 2005;32(7):1232-42"},{"issue":"6","key":"11602_CR85","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3899\/jrheum.091466","volume":"37","author":"JA Singh","year":"2010","unstructured":"Singh JA, Noorbaloochi S, Singh G (2010) Golimumab for rheumatoid arthritis: a systematic review. J Rheumatol 37(6):1096\u20131104","journal-title":"J Rheumatol"},{"issue":"3","key":"11602_CR86","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1136\/annrheumdis-2013-204195","volume":"74","author":"J Kay","year":"2015","unstructured":"Kay J et al (2015) Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis 74(3):538-46","journal-title":"Ann Rheum Dis"},{"key":"11602_CR87","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/14740338.2017.1273899","volume":"16","author":"J Braun","year":"2017","unstructured":"Braun J, Kay J (2017) The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. Expert Opin Drug Saf 16:289\u2013302","journal-title":"Expert Opin Drug Saf"},{"key":"11602_CR88","doi-asserted-by":"crossref","unstructured":"Ruiz Garcia V et al (2017) Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Reviews 9","DOI":"10.1002\/14651858.CD007649.pub4"},{"issue":"2","key":"11602_CR89","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117(2):244\u2013279. https:\/\/doi.org\/10.1016\/j.pharmthera.2007.10.001","journal-title":"Pharmacol Ther"},{"issue":"7","key":"11602_CR90","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/rheumatology\/keq032","volume":"49","author":"T Horiuchi","year":"2010","unstructured":"Horiuchi T, Shimoyama H, Yokoyama H (2010) Structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 49(7):1215\u20131229. https:\/\/doi.org\/10.1093\/rheumatology\/keq032","journal-title":"Rheumatology (Oxford)"},{"key":"11602_CR91","doi-asserted-by":"publisher","first-page":"CD008794","DOI":"10.1002\/14651858.CD008794.pub2","volume":"2","author":"JA Singh","year":"2011","unstructured":"Singh JA, Wells GA, Christensen R et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2:CD008794. https:\/\/doi.org\/10.1002\/14651858.CD008794.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"11602_CR92","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/art.20009","volume":"50","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K, Anderson J, Urbansky K (2004) Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50:372\u2013379. https:\/\/doi.org\/10.1002\/art.20009","journal-title":"Arthritis Rheum"},{"key":"11602_CR93","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1086\/506935","volume":"43","author":"P Brassard","year":"2006","unstructured":"Brassard P, Kezouh A, Suissa S (2006) Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43:717\u2013722. https:\/\/doi.org\/10.1086\/506935","journal-title":"Clin Infect Dis"},{"key":"11602_CR94","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P et al (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy. Arth Rheum 60:1884\u20131894. https:\/\/doi.org\/10.1002\/art.24632","journal-title":"Arth Rheum"},{"key":"11602_CR95","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2009.146","volume":"301","author":"A Strangfeld","year":"2009","unstructured":"Strangfeld A, Listing J, Herzer P et al (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301:737\u2013744. https:\/\/doi.org\/10.1001\/jama.2009.146","journal-title":"JAMA"},{"key":"11602_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15100","volume":"15","author":"M Rodgers","year":"2011","unstructured":"Rodgers M, Epstein D, Bojke L et al (2011) Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 15:1\u2013329. https:\/\/doi.org\/10.3310\/hta15100","journal-title":"Health Technol Assess"},{"key":"11602_CR97","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","volume":"317","author":"E Baecklund","year":"1998","unstructured":"Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317:180\u2013181. https:\/\/doi.org\/10.1136\/bmj.317.7152.180","journal-title":"BMJ"},{"key":"11602_CR98","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/pds.2046","volume":"20","author":"J Askling","year":"2011","unstructured":"Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D (2011) Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 20:119\u2013130. https:\/\/pubmed.ncbi.nlm.nih.gov\/21254282\/","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"11602_CR99","doi-asserted-by":"publisher","first-page":"CD007649","DOI":"10.1002\/14651858.CD007649.pub2","volume":"2","author":"V Ruiz Garcia","year":"2011","unstructured":"Ruiz Garcia V, Jobanputra P, Burls A et al (2011) Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2:CD007649. https:\/\/doi.org\/10.1002\/14651858.CD007649.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"11602_CR100","first-page":"CD008341","volume":"1","author":"JA Singh","year":"2010","unstructured":"Singh JA, Noorbaloochi S, Singh G (2010) Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev 1:CD008341. https:\/\/pubmed.ncbi.nlm.nih.gov\/20091667\/ doi: 10.1002\/14651858.CD008341","journal-title":"Cochrane Database Syst Rev"},{"key":"11602_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0048991","volume":"7","author":"G Moulis","year":"2012","unstructured":"Moulis G, Sommet A, Bene J et al (2012) Cancer risk of anti-TNF at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS ONE 7:1\u20137. https:\/\/doi.org\/10.1371\/journal.pone.0048991","journal-title":"PLoS ONE"},{"key":"11602_CR102","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/art.37931","volume":"65","author":"G Sommet","year":"2013","unstructured":"Sommet G, Lapeyre-Mestre A (2013) Mortality rates among patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: comment on the article by Simard. Arthitis Rheum 65:1670\u20131671. https:\/\/doi.org\/10.1002\/art.37931","journal-title":"Arthitis Rheum"},{"key":"11602_CR103","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1136\/ard.2010.149419","volume":"70","author":"X Mariette","year":"2011","unstructured":"Mariette X, Matucci-Cerinic M, Pavelka K et al (2011) Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895\u20131904. https:\/\/pubmed.ncbi.nlm.nih.gov\/21885875\/","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"11602_CR104","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/mr\/roac123","volume":"33","author":"T Ishii","year":"2023","unstructured":"Ishii T, Tanaka Y (2023) Ozoralizumab, a humanized anti\u2013TNF-\u03b1 VHH antibody, for the treatment of rheumatoid arthritis: structural features, pharmacokinetics, efficacy, and safety data from the OHZORA trial. Mod Rheumatol 33(1):123\u2013134. https:\/\/doi.org\/10.1093\/mr\/roac123","journal-title":"Mod Rheumatol"},{"key":"11602_CR105","doi-asserted-by":"publisher","first-page":"108917","DOI":"10.1016\/j.clim.2022.108917","volume":"235","author":"Y Haruna","year":"2022","unstructured":"Haruna Y et al (2022) Recent advancement of fragmented immunoglobulin molecules targeting TNF-\u03b1: focus on the first approved nanobody for RA, ozoralizumab. Clin Immunol 235:108917. https:\/\/doi.org\/10.1016\/j.clim.2022.108917","journal-title":"Clin Immunol"},{"key":"11602_CR106","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F et al (2012) PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161:505\u2013522. https:\/\/pubmed.ncbi.nlm.nih.gov\/22353619\/","journal-title":"J Control Release"},{"key":"11602_CR107","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13075-020-02230-y","volume":"22","author":"YJ Ha","year":"2020","unstructured":"Ha YJ et al (2020) Methotrexate-loaded multifunctional nanoparticles with near-infrared irradiation for the treatment of rheumatoid arthritis. Arthritis Res Ther 22:146. https:\/\/pubmed.ncbi.nlm.nih.gov\/32552859\/","journal-title":"Arthritis Res Ther"},{"key":"11602_CR108","doi-asserted-by":"publisher","first-page":"120390","DOI":"10.1016\/j.biomaterials.2020.120390","volume":"264","author":"Y Yang","year":"2021","unstructured":"Yang Y et al (2021) Targeted silver nanoparticles for rheumatoid arthritis therapy via macrophage apoptosis and Re-polarization. Biomaterials 264:120390. https:\/\/pubmed.ncbi.nlm.nih.gov\/32980634\/","journal-title":"Biomaterials"},{"issue":"10086","key":"11602_CR109","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/S2665-9913(22)00337-8","volume":"389","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Pope JE (2017) Novel treatment strategies in rheumatoid arthritis. The Lancet 389(10086):2338-48. https:\/\/doi.org\/10.1016\/S2665-9913(22)00337-8","journal-title":"Lancet"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11602-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11602-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11602-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T21:03:44Z","timestamp":1771967024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11602-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11602"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11602-7","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"413"}}